

IPR & Innovation

1. [Rod Hunter: Why India needs stronger IPR](#) – Business Standard

Regulatory & Medical

1. [India taking legal advice on EU's medicine ban: Commerce Secretary Rita Teotia](#) – Economic Times

Same appeared in:

[DNA](#)

[Business Standard](#)

Access to Healthcare

1. [Price control on drugs a shot in the arm for health care: Subburaj](#) – Business Standard
2. [Free competition only way to ensure low cost life-saving drugs: Cipla to govt](#) – DNA
3. [Cipla urges government to support capital investment, R&D for pharma industry](#) - Economic Times

Others

1. [Indian pharma sector can grow fivefold in 10 to 15 years: Officials](#) – Business Standard
 2. [A horse before a cart](#) – Mint
 3. [Subject wise - Innovation in Medicine](#) – Times of India
-

IPR & Innovation

1. [Rod Hunter: Why India needs stronger IPR](#) – Business Standard

Earlier this year, the market capitalisation of Apple surpassed \$700 billion - marking the first time a US company had ever reached that milestone. One of the factors contributing to Apple's strong performance has been its investments in research and development. And the company is doubling down on those investments. Its R&D spending surged to \$1.9 billion in the second quarter of its fiscal year - a 36 per cent increase relative to a year earlier. Apple says R&D investments are "critical" to its "future growth and competitive position in the marketplace and are directly related to timely development of new and enhanced products that are central to the Company's core business strategy."

Regulatory & Medical

1. [India taking legal advice on EU's medicine ban: Commerce Secretary Rita Teotia](#) – Economic Times

India is seeking "legal advice" to deal with the recent ban imposed by the European Union on 700 medicines which were clinically tested by GVK Biosciences, a top official said. "We are certainly exploring what are the options for India. We are taking legal advice... We will take a call on this to move forward," Commerce Secretary Rita Teotia told PTI. The largest EU-wide suspension of sales and distribution of generic drugs ordered by the European Commission has already come into effect and is applicable to all 28 member nations, according to Germany's drug regulator, the Federal Institute for Medicines and Medical Products (BfArM).

Access to Healthcare

1. [Price control on drugs a shot in the arm for health care: Subburaj](#) – Business Standard
Price control on drugs helps improve accessibility and is key to making health care affordable, a top official in the department of pharmaceuticals said, even as the industry continues to make representations to the government against such a move. "The government cannot do away with it," V K Subburaj, secretary of the department, told Business Standard when asked whether there's a rethink on the issue.
2. [Free competition only way to ensure low cost life-saving drugs: Cipla to govt](#) - DNA
Pharmaceutical major Cipla has urged the government to focus on supporting capital investment, encouraging R&D and create a favourable tax regime to help growth of the pharma industry, instead of just regulating prices. In the US alone, Indian pharma companies have a 30-40% share of the total generics market. Apart from traditional generics, India's capabilities now extend to complex drugs and newer delivery systems in many areas such as oncology, respiratory and HIV/AIDS, Cipla Chairman Y K Hamied said.
3. [Cipla urges government to support capital investment, R&D for pharma industry](#) - Economic Times
Pharma major CiplaBSE 0.87 % has urged the government to focus on supporting capital investment, encouraging research and development and create a favourable tax regime to help growth of the pharma industry, instead of just regulating prices. "The government should bring in attractive market conditions by supporting capital investment, encourage R&D and create a favourable tax environment," said Cipla chairman YK Hamied.

Others

1. [Indian pharma sector can grow fivefold in 10 to 15 years: Officials](#) – Business Standard
India's pharmaceutical sector can grow five times in the next 10 to 15 years and innovation should act as a catalyst in the growth process, a senior official said here on Friday. "While India has achieved a good position in generic drugs and is self reliant but India has the potential to become a drug discovery destination. The generic drug market may grow another five times over a period of time - another 10 or 15 years and drug innovation should act as a catalyst to that growth," V.K. Subburaj, secretary in department of pharmaceuticals of the chemicals and fertilizers ministry, told IANS here on the sidelines of an event here.
2. [A horse before a cart](#) - Mint
Two things over the last few weeks have got me thinking anew about health and medical care in India. The first was a week-long stay, with my daughter, at the Jindal Naturecure Institute (JNI) in Bengaluru. JNI is a rather severe place, where they put you on a fasting diet for days and load you with yoga, mudpacks and massages. It is a great place to be from—one returns cleansed and trim. The second was a set of excellent discussions on healthcare at the just concluded TiE LeapFrog conference—a conference on strategic disruptions in different business verticals. David Lawrence, a former chairman of Kaiser Permanente Healthcare, stressed the need for India to drive healthcare in greater measure rather than simply focus on medical care.
3. [Subject wise - Innovation in Medicine](#) – Times of India
Academics from the US and UK give an overview of research in medicine and the opportunities it offers Lloyd B Minor, dean, Stanford University School of Medicine, US. Research in the fields of biology and medicine presents both, challenges and opportunities. At a time of decreased funding for research, there is also an increasing importance of research to foster innovation. Many of the biggest challenges in biomedical research today do not divide neatly into academic divisions and departments; they require large and diverse teams of collaborators. Supporting these collaborations is key to driving novel discoveries in basic and translational research, and thereby, innovation in science and clinical medicine.